2023 World Conference on Lung Cancer (Posters)-P2.11. A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer

P2.11. A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A phase 2 study evaluated the efficacy and safety of tepotinib, a selective MET tyrosine kinase inhibitor, in patients with advanced solid cancers harboring MET exon 14 skipping mutation or amplification. The study focused on non-small cell lung cancer (NSCLC) patients. A total of 35 patients received tepotinib, with 24 of them being NSCLC patients. The majority of NSCLC patients had MET exon 14 skipping mutation. The objective response rate (ORR) to tepotinib was 60.9% and the disease control rate (DCR) was 100% in NSCLC patients. The median progression-free survival (PFS) was 9.0 months for patients with MET exon 14 skipping mutation. The main adverse events of tepotinib were low-grade and manageable, with peripheral edema being the most frequent. Liquid biopsy using next-generation sequencing (NGS) was used to detect MET exon 14 skipping mutation, which showed a high ORR of 72.7% in positive patients compared to 33.3% in negative patients.<br /><br />The study concluded that tepotinib demonstrated favorable antitumor activity in NSCLC patients with MET exon 14 skipping mutation or amplification. Patients with MET exon 14 skipping mutation showed a durable response to tepotinib. The low-grade adverse events and the potential role of liquid biopsy in predicting tepotinib response were highlighted. The study was supported by grants from the Korea Health Technology R&D Project, the National R&D Program for Cancer Control, and Merck KGaA.

Asset Subtitle

Yaewon Yang

Meta Tag

Speaker Yaewon Yang

Topic Metastatic NSCLC: Targeted Therapy - KRAS/MET

Keywords

tepotinib

MET tyrosine kinase inhibitor

MET exon 14 skipping mutation

non-small cell lung cancer

objective response rate

disease control rate

progression-free survival

adverse events

liquid biopsy

next-generation sequencing